Immunogenicity and reactogenicity of an inactivated varicella zoster virus vaccine in patients with autoimmune disease

Trial Profile

Immunogenicity and reactogenicity of an inactivated varicella zoster virus vaccine in patients with autoimmune disease

Completed
Phase of Trial: Phase II

Latest Information Update: 04 Jan 2014

At a glance

  • Drugs Varicella zoster virus vaccine live (Primary)
  • Indications Chickenpox; Varicella zoster virus infections
  • Focus Pharmacodynamics
  • Sponsors Merck & Co
  • Most Recent Events

    • 04 Jan 2014 Results published in Arthritis and Rheumatism.
    • 04 Jan 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top